BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1229 related articles for article (PubMed ID: 20797419)

  • 1. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
    Danhier F; Feron O; Préat V
    J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-based targeted therapy for cancer tissue.
    Das M; Mohanty C; Sahoo SK
    Expert Opin Drug Deliv; 2009 Mar; 6(3):285-304. PubMed ID: 19327045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive and active drug targeting: drug delivery to tumors as an example.
    Torchilin VP
    Handb Exp Pharmacol; 2010; (197):3-53. PubMed ID: 20217525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer drug delivery with nanoparticles.
    Conti M; Tazzari V; Baccini C; Pertici G; Serino LP; De Giorgi U
    In Vivo; 2006; 20(6A):697-701. PubMed ID: 17203748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in polymeric micelles for drug delivery and tumor targeting.
    Kedar U; Phutane P; Shidhaye S; Kadam V
    Nanomedicine; 2010 Dec; 6(6):714-29. PubMed ID: 20542144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of nanocarrier systems in cancer nanotherapy.
    Mozafari MR; Pardakhty A; Azarmi S; Jazayeri JA; Nokhodchi A; Omri A
    J Liposome Res; 2009; 19(4):310-21. PubMed ID: 19863166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.
    Huang S; Shao K; Liu Y; Kuang Y; Li J; An S; Guo Y; Ma H; Jiang C
    ACS Nano; 2013 Mar; 7(3):2860-71. PubMed ID: 23451830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.
    Alexiou C; Jurgons R; Schmid RJ; Bergemann C; Henke J; Erhardt W; Huenges E; Parak F
    J Drug Target; 2003 Apr; 11(3):139-49. PubMed ID: 13129824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
    Danhier F; Ucakar B; Magotteaux N; Brewster ME; Préat V
    Int J Pharm; 2010 Jun; 392(1-2):20-8. PubMed ID: 20226846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organic nanocarriers for cancer drug delivery.
    López-Dávila V; Seifalian AM; Loizidou M
    Curr Opin Pharmacol; 2012 Aug; 12(4):414-9. PubMed ID: 22465543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of nanoparticles in cancer: drug delivery and diagnostics.
    Talekar M; Kendall J; Denny W; Garg S
    Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting liposomes toward novel pediatric anticancer therapeutics.
    Federman N; Denny CT
    Pediatr Res; 2010 May; 67(5):514-9. PubMed ID: 20118828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
    Bharali DJ; Mousa SA
    Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active targeting of brain tumors using nanocarriers.
    Béduneau A; Saulnier P; Benoit JP
    Biomaterials; 2007 Nov; 28(33):4947-67. PubMed ID: 17716726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
    Maeda H; Bharate GY; Daruwalla J
    Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance].
    Chen JN; Shen Q; Li SS
    Yao Xue Xue Bao; 2009 Apr; 44(4):333-7. PubMed ID: 19545047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle and targeted systems for cancer therapy.
    Brannon-Peppas L; Blanchette JO
    Adv Drug Deliv Rev; 2004 Sep; 56(11):1649-59. PubMed ID: 15350294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metallic nanoparticles: technology overview & drug delivery applications in oncology.
    Ahmad MZ; Akhter S; Jain GK; Rahman M; Pathan SA; Ahmad FJ; Khar RK
    Expert Opin Drug Deliv; 2010 Aug; 7(8):927-42. PubMed ID: 20645671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.
    Sultana S; Khan MR; Kumar M; Kumar S; Ali M
    J Drug Target; 2013 Feb; 21(2):107-25. PubMed ID: 22873288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.